These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 11295099

  • 1. Regulation of BRCA1 and BRCA2 transcript in response to cisplatin, adriamycin, taxol and ionising radiation is correlated to p53 functional status in ovarian cancer cell lines.
    Aunoble B, Bernard-Gallon D, Bignon YJ.
    Oncol Rep; 2001; 8(3):663-8. PubMed ID: 11295099
    [Abstract] [Full Text] [Related]

  • 2. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.
    Andres JL, Fan S, Turkel GJ, Wang JA, Twu NF, Yuan RQ, Lamszus K, Goldberg ID, Rosen EM.
    Oncogene; 1998 Apr 30; 16(17):2229-41. PubMed ID: 9619832
    [Abstract] [Full Text] [Related]

  • 3. Down-regulation of BRCA1 and BRCA2 in human ovarian cancer cells exposed to adriamycin and ultraviolet radiation.
    Fan S, Twu NF, Wang JA, Yuan RQ, Andres J, Goldberg ID, Rosen EM.
    Int J Cancer; 1998 Aug 12; 77(4):600-9. PubMed ID: 9679765
    [Abstract] [Full Text] [Related]

  • 4. [Effects of wild-type p53 gene on the chemotherapy sensitivity of ovarian cancer SKOV-3 cells to cisplatin].
    Jin Z, Guan T, Li S.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Jun 12; 19(3):218-20. PubMed ID: 12048682
    [Abstract] [Full Text] [Related]

  • 5. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation.
    DelloRusso C, Welcsh PL, Wang W, Garcia RL, King MC, Swisher EM.
    Mol Cancer Res; 2007 Jan 12; 5(1):35-45. PubMed ID: 17259345
    [Abstract] [Full Text] [Related]

  • 6. Ultraviolet irradiation induces BRCA2 protein depletion through a p53-independent and protein synthesis-dependent pathway.
    Wang SC, Makino K, Su LK, Pao AY, Kim JS, Hung MC.
    Cancer Res; 2001 Apr 01; 61(7):2838-42. PubMed ID: 11306454
    [Abstract] [Full Text] [Related]

  • 7. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
    Puca R, Nardinocchi L, Pistritto G, D'Orazi G.
    Gynecol Oncol; 2008 Jun 01; 109(3):403-10. PubMed ID: 18395248
    [Abstract] [Full Text] [Related]

  • 8. The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells.
    Zhou C, Huang P, Liu J.
    Biochem Biophys Res Commun; 2005 Oct 28; 336(3):952-60. PubMed ID: 16165098
    [Abstract] [Full Text] [Related]

  • 9. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance.
    Vasey PA, Jones NA, Jenkins S, Dive C, Brown R.
    Mol Pharmacol; 1996 Dec 28; 50(6):1536-40. PubMed ID: 8967975
    [Abstract] [Full Text] [Related]

  • 10. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line.
    Wu GS, Ding Z.
    Oncogene; 2002 Jan 03; 21(1):1-8. PubMed ID: 11791171
    [Abstract] [Full Text] [Related]

  • 11. UVC inhibits HIF-1alpha protein translation by a DNA damage- and topoisomerase I-independent pathway.
    Rapisarda A, Melillo G.
    Oncogene; 2007 Oct 18; 26(48):6875-84. PubMed ID: 17496931
    [Abstract] [Full Text] [Related]

  • 12. p53 inhibits adriamycin-induced down-regulation of cyclin D1 expression in human cancer cells.
    Shao J, Teraishi F, Katsuda K, Tanaka N, Fujiwara T.
    Biochem Biophys Res Commun; 2002 Jan 25; 290(3):1101-7. PubMed ID: 11798189
    [Abstract] [Full Text] [Related]

  • 13. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
    Kolfschoten GM, Hulscher TM, Schrier SM, van Houten VM, Pinedo HM, Boven E.
    Gynecol Oncol; 2002 Mar 25; 84(3):404-12. PubMed ID: 11855878
    [Abstract] [Full Text] [Related]

  • 14. BRCA1 is differentially expressed in human tumor cells.
    Meng QH, Yuan RQ, Goldberg ID, Rosen EM, Fan SJ.
    Shi Yan Sheng Wu Xue Bao; 2001 Mar 25; 34(1):55-64. PubMed ID: 12549011
    [Abstract] [Full Text] [Related]

  • 15. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells.
    Abedini MR, Muller EJ, Brun J, Bergeron R, Gray DA, Tsang BK.
    Cancer Res; 2008 Jun 15; 68(12):4511-7. PubMed ID: 18559494
    [Abstract] [Full Text] [Related]

  • 16. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines.
    Metzinger DS, Taylor DD, Gercel-Taylor C.
    Cancer Lett; 2006 May 18; 236(2):302-8. PubMed ID: 15990222
    [Abstract] [Full Text] [Related]

  • 17. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway.
    Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S.
    Oncogene; 2002 Apr 18; 21(17):2613-22. PubMed ID: 11965534
    [Abstract] [Full Text] [Related]

  • 18. Identification and functional characterization of a novel unspliced transcript variant of HIC-1 in human cancer cells exposed to adverse growth conditions.
    Mondal AM, Chinnadurai S, Datta K, Chauhan SS, Sinha S, Chattopadhyay P.
    Cancer Res; 2006 Nov 01; 66(21):10466-77. PubMed ID: 17079468
    [Abstract] [Full Text] [Related]

  • 19. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
    Villedieu M, Louis MH, Dutoit S, Brotin E, Lincet H, Duigou F, Staedel C, Gauduchon P, Poulain L.
    Gynecol Oncol; 2007 Apr 01; 105(1):31-44. PubMed ID: 17275076
    [Abstract] [Full Text] [Related]

  • 20. Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells.
    Di X, Gennings C, Bear HD, Graham LJ, Sheth CM, White KL, Gewirtz DA.
    Breast Cancer Res Treat; 2010 Nov 01; 124(2):349-60. PubMed ID: 20155316
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.